Bronchiolitis Associated With *Mycoplasma Pneumoniae* in Infants in Suzhou China Between 2010 and 2012

Yuqing Wang¹, Chuangli Hao¹, Wei Ji¹, Yongdong Yan¹, Xuejun Shao² & Jun Xu²

¹Department of Respiratory Medicine, The Affiliated Children’s Hospital, Soochow University, Suzhou 215003, China, ²Department of Lab Medicine, The Affiliated Children’s Hospital, Soochow University, Suzhou 215003, China.

Viruses cause most cases of bronchiolitis in infants; consequently the importance of other agents such as *Mycoplasma pneumoniae* (MP) in the etiology of bronchiolitis may not be fully recognized. We investigated the prevalence and seasonal distribution of bronchiolitis caused by MP in 674 children admitted to the Children’s Hospital affiliated with Soochow University from January 2010 to December 2012. The presence of MP was confirmed by real-time PCR. During the 3 years, we identified MP in 17.2% of the children with bronchiolitis. The annual MP detection rates were 16.6% in 2010, 17.8% in 2011, and 17.2% in 2012. MP was detected throughout the year, with a peak from July to September. The median age of MP-positive children was 10 months. Common clinical manifestations included cough, wheezing, and high fever. Moist and/or wheezing rales were frequent, and pulmonary interstitial infiltration was seen in 66.4% of chest X-rays. Patients with MP infection were older, were more likely to have pulmonary interstitial infiltration, and had shorter hospital stays than those with respiratory syncytial virus infection. Our study revealed MP as an important cause of bronchiolitis, with peaks of occurrence during the summer and early autumn. Pulmonary interstitial infiltrations were a common event.

**Results**

**Patient characteristics.** A total of 674 patients with bronchiolitis were studied, including 225 cases in 2010, 205 in 2011, and 244 in 2012. There were 457 (67.8%) male and 217 (32.2%) female patients. 247 (36.6%) were younger than 6 months of age, 234 (34.7%) were 6 months–1 year of age, 193 (28.6%) were 1–2 years of age. The youngest patient was 35 days old, and the oldest patient was 2 years of age.

**Pathogens detected.** Pathogens were identified in 586 of 674 specimens (86.9%). RSV was found in 343 cases (50.9%), MP in 116 cases (17.2%), parainfluenza virus (PIV) III in 41 cases (6.1%), human bocavirus (hBoV) in 36 cases (5%), human metapneumovirus (hMPV) in 34 cases (5%), influenza virus B (IVB) in nine cases (1.3%), influenza virus A (IVA) in six cases (0.9%), and PIV II in one case (0.1%). Mixed infection was observed in 35...
cases, including 16 of MP + hBoV (45.7%), four of hMPV + hBoV (11.4%), four of hBoV + PIV III (11.4%), 3 cases of RSV + IVA (8.6%), three cases of RSV + hBoV (8.6%), three cases of hMPV + RSV (8.6%), and two cases of hMPV + PIV III (5.7%), respectively.

Prevalence of MP and RSV infections in different years and seasons. The annual MP-positive rates were 16.6% (2010), 17.8% (2011), and 17.2% (2012). MP was detected throughout the year with a epidemic peaks observed each year between July and September. The lowest MP-positive rates were January to February and November to December each year. The seasons in the Suzhou area of China were defined as spring (March–May), summer (June–August), autumn (September–November), and winter (December–February). The peaks of MP occurrence thus occurred in the summer and early autumn. The highest rates occurred in September 2010 (44.4%), August 2011 (62.5%), and July 2012 (58.3%), showing a peak that occurred earlier in successive years and higher infection rates in 2011 and 2012 than in 2010. The highest rates of RSV infection were seen to occur between November of one year and March of the following year. The lowest RSV-positive rates were observed each year between June and September. (Figure 1).

Prevalence of MP infection differed with age but not sex. Among the 116 cases of MP infection, the youngest patient was 2 months and the oldest was 2 years of age. The median age was 10 months (range: 6–15 months); 22 cases (19%) were less than 6 months of age, 56 (48.3%) were 6 months to 1 year, 38 (32.7%) were 1–2 years of age. The MP positivity rate in patients between 6 months and 1 year of age was significantly higher than that in other age groups ($P < 0.01$). Sixty cases occurred in males and 56 in females ($M : F = 1.07 : 1$). The difference was not statistically significant.

Clinical characteristics of patients infected with MP. Various degrees of fever were recorded in 38 cases (32.8%). The median duration of fever was 3.5 ± 1.0 days. Patients had differing severity of cough and wheezing; there were 13 cases (11.2%) of tachypnea or dyspnea, seven (6%) of $O_2$ saturation < 90%, and 98 cases (84.5%) of lung rales and (or) wheezing.

The median white blood cell counts were $7.7 \pm 3.5 \times 10^9/l$, mean C-reactive protein (CRP) was $8.5 \pm 3.8$ mg/l; 79 cases (68.1%) had peripheral blood platelet counts $> 400 \times 10^9/l$. Thirty patients (25.8%) had elevated alanine aminotransferase (ALT) levels, 41 (35.5%) had elevated creatine kinase MB isoenzyme (CK-MB). The radiological analysis was performed by a radiologist blinded to the pathogens that had been isolated. Abnormal chest X-ray findings were seen in 332 patients (88.3%), including 77 cases (66.4%) of pulmonary interstitial infiltration, 14 (12.1%) of patchy shadows, and 19 (16.4%) of emphysema. Thirty-three cases had vomiting and/or diarrhea. All patients improved or were cured, and were discharged from hospital. The average hospital stay was 7 days (range, 6.3–9.0 days; Table 1).

Characteristics of patients with MP or RSV infection. The average age was 10 months in MP patients and 5.2 months in RSV patients. Low fever was more common in children with RSV than MP infection, and high fever was more common in MP than RSV infection. $SaO_2 < 90\%$ was more common in children with RSV than MP infection. Thrombocytosis, increased ALT and CK-MB were more common in children with MP infection than those with RSV infection. Pulmonary interstitial infiltration was more common in children infected with MP than those with RSV (Figure 2). Emphysema was more common in children with RSV than those with MP infection (Figure 3). The average hospital stay was longer in children with RSV than those with MP infection (Table 2).

Discussion

In this study, MP was the second most frequently identified bronchiolitis pathogen after RSV, found in 17.2% of the cases. The detection rate of MP was higher than that in previous reports. Liu WK et al.\(^\text{15}\) reported an MP-positive rate of 11.3% in children with acute respir-

![Figure 1](https://www.nature.com/scientificreports)


Table 1 | Overall characteristics of patients with MP bronchiolitis

| Characteristics               | No. of patients (%) |
|-------------------------------|---------------------|
| Age                           |                     |
| <6 months                     | 22 (8.9)            |
| 6 months–1 year               | 56 (23.9)           |
| 1–2 years                     | 36 (18.6)           |
| Sex                           |                     |
| Male                          | 60 (51.7)           |
| Female                        | 56 (48.3)           |
| Fever (°C)                    |                     |
| <38                           | 1 (5.6%)            |
| 38–39                         | 5 (13.1%)           |
| >39                           | 32 (37.2%)          |
| Symptom                       |                     |
| Cough                         | 116 (100)           |
| Wheezing                      | 116 (100)           |
| Tachypnea                     | 13 (11.2)           |
| Dypsnea                       | 13 (11.2)           |
| Vomiting/diarrhea             | 33 (28.4)           |
| Physical examination          |                     |
| Lung wheezing rales           | 89 (76.7)           |
| Lung crackles                 | 9 (7.8)             |
| SaO2 ≤ 90%                    | 7 (6)               |
| Lab test                      |                     |
| WBC ($\times 10^{9}$/l)       | 7.7 ± 3.5           |
| CRP (mg/l)                    | 8.5 ± 3.8           |
| Blood platelet counts ≥ 400 × $10^{9}$/l | 79 (68.1)  |
| ALT                           | 30 (25.8)           |
| CK-MB                         | 41 (35.5)           |
| Abnormal chest X-ray          |                     |
| Interstitial infiltration     | 77 (65.4)           |
| Patchy shadows                | 14 (12.1)           |
| Emphysema                     | 19 (16.4)           |

Data are expressed as number of patients (%) unless otherwise indicated. WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.

We note that a PCR assay may reveal small numbers of organisms that are not the cause of infection. Therefore, a highly sensitive detection method such as non-quantitative PCR may overestimate the clinical importance of M pneumoniae as a pathogen. The results obtained with the method as used here (i.e., qRT-PCR, Ct curves) depended on the amount of target sequence in the starting (clinical) sample, and although there is no agreement on the CCU/ml indicative of infection, a cutoff value was chosen based on the available published data. The reasons we considered these patients were infected rather than colonized by *M. pneumoniae* are as follows.

1) The patients were being treated for a current diagnosis of bronchiolitis. All had ongoing clinical manifestations of lower respiratory tract infection. 2) We used quantitative PCR to detect MP-DNA in patient sputum. 3) The cutoff value for the detected copy number in the MP-PCR assay was set at $>10^4$ CCU/ml for MP infection. A specific threshold for *Mycoplasma* in the respiratory tract that can differentiate colonization from infection has not been established, however a cutoff value for the detected copy number in the MP-PCR assay was set at $>10^4$ CCU/ml. We believe that $<10^5$ CCU/ml is generally considered as indicative of colonization. Skakni et al. used a semiquantitative PCR technique to detect *M. pneumoniae* DNA in clinical samples, and reported high loads ($\geq 10^5$ to $\geq 10^6$ CCU/ml) of *M. pneumoniae* were found in 8 of 10 patients with acute pneumonia, and low loads ($<10^5$ CCU/ml) in were found in samples from asymptomatic patients. Kleemola et al. used a commercial Gen-Probe probe test during an epidemic of *M. pneumoniae* infections among army conscripts. Comparison of the probe test results with the *Mycoplasma* culture and serologic results showed that the probe test was sensitive and specific for the rapid diagnosis of acute *M. pneumoniae* infection of the lower respiratory tract when sputum was used. It had good sensitivity (0.95) and specificity (0.85) among patients whose serologic results were consistent with their culture results.

This is the largest study of MP-caused bronchiolitis in infants and included a series of patients in the Suzhou region over 3 consecutive years. Our data revealed that MP can be detected throughout the year with a peak prevalence between July and September each year, suggesting that the epidemic MP season in the Suzhou region is in summer and early autumn. A previous epidemiological study by Ji et al is consistent with the seasonal pattern presented in this study. Respiratory tract infections caused by other pathogens are relatively infrequent at that time. Contrary to this finding, Hadil et al reported a higher prevalence of MP in autumn and only a few cases in winter and spring. MP...
was not detected in summer. Defilippi et al.\textsuperscript{4} reported the first MP peak in June, and a second peak in December and January. Sidal et al.\textsuperscript{25} reported the highest prevalence of MP was in winter. But one report including data collected over 11 consecutive years showed that the prevalence of MP had no obvious seasonal differences\textsuperscript{24}. Overall, the available studies suggest that the epidemiology of MP differs from region to region because of differences in climate.

Previous studies suggested that MP infections occurred mainly in school-age children and adolescents, with the highest prevalence in patients between 5 and 14 years of age\textsuperscript{26}. MP infection in infants was relatively rare\textsuperscript{27}. However, this study found that MP bronchiolitis was seen mainly in infants from 6 months to 1 year of age and had a detection rate 23.9% in that group of patients. Evidence that MP seen mainly in infants from 6 months to 1 year of age and had a peak in June, and a second peak in December and January. Sidal et al.\textsuperscript{25} reported the highest prevalence of MP was in winter. But one report including data collected over 11 consecutive years showed that the prevalence of MP had no obvious seasonal differences\textsuperscript{24}. Overall, the available studies suggest that the epidemiology of MP differs from region to region because of differences in climate.

Table 2 | Characteristics of patients with bronchiolitis caused by MP or RSV

| Characteristic | MP [n = 116], n (%) | RSV [n = 343], n (%) | χ²/Z test | P |
|---------------|---------------------|----------------------|-----------|---|
| Mean age [months (range)] | 10.0 (6.0–15.0) | 5.2 (3.0–9.0) | 8.11 | <0.001 |
| <6 months | 22 (19) | 208 (60.6) | 60.224 | <0.001 |
| 6 months–1 year | 56 (48.3) | 84 (24.5) | 23.1362 | <0.001 |
| 1–2 years | 38 (32.7) | 51 (14.9) | 17.7494 | <0.001 |
| Sex | Male | 60 (51.7) | 257 (74.9) | 21.84 | <0.001 |
| | Female | 56 (48.3) | 86 (25.1) | 21.8426 | <0.001 |
| Fever (°C) | <38 | 38 (32.8) | 92 (26.8) | 1.51 | >0.05 |
| | 38–39 | 1 (5.6) | 80 (23.3) | 30.09 | <0.001 |
| | >39 | 5 (13.1) | 11 (3.2) | 0.07 | >0.05 |
| Symptom | Cough | 116 (100) | 340 (99.1) | Fisher’s | 0.5751 |
| | Wheezing | 116 (100) | 343 (100) | Fisher’s | 1 |
| | Tachypnea | 13 (11.2) | 98 (28.6) | 14.2557 | <0.001 |
| | Dyspnea | 13 (11.2) | 86 (25.1) | 9.8521 | 0.0017 |
| | Vomiting/diarrhea | 33 (28.4) | 67 (19.8) | 4.0429 | 0.0444 |
| Physical examination | Lung wheezing rales | 89 (76.7) | 270 (79.6) | 0.2021 | 0.6531 |
| | Lung crackles | 9 (7.8) | 32 (9.3) | 0.2629 | 0.6081 |
| | SaO₂ < 90% | 7 (6.0) | 89 (25.9) | 20.78 | <0.001 |
| Lab tests | WBC (×10⁹/L) ± SEM | 7.7 ± 3.5 | 7.2 ± 2.9 | 9.84 | <0.05 |
| | CRP (mg/L) ± SEM | 8.5 ± 3.8 | 7.6 ± 2.3 | 10.02 | <0.05 |
| | Platelet count > 400 × 10⁶/L | 79 (68.1) | 109 (31.7) | 15.3 | <0.05 |
| | ALT | 30 (25.8) | 31 (9) | 21.29 | <0.001 |
| | CK-MB | 41 (35.5) | 33 (9.6) | 42.42 | <0.001 |
| Chest X-ray | Patchy shadow | 14 (12.1) | 68 (19.8) | 3.55 | >0.05 |
| | Pulmonary emphysema | 19 (16.4) | 231 (67.3) | 90.79 | <0.001 |
| | Pulmonary interstitial infiltration | 77 (66.4) | 44 (12.8) | 128.06 | <0.001 |
| | Mean hospital stay [days (range)] | 7.0 (6.3–9.0) | 8.0 (7.0–9.0) | 5.73 | <0.001 |

Data are expressed as number of patients (%) unless otherwise indicated.

MP, Mycoplasma pneumoniae; RSV, respiratory syncytial virus; WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.
The major limitation of this study was that serological examinations of MP and other pathogens were absent. Another limitation was the absence of asymptomatic control patients. There was also no standard scoring system to distinguish the different patterns in chest X-ray examinations of patients. We plan to conduct a more extensive study in the near future to address these issues.

**Methods**

**Approvals.** All experiments were performed following the relevant guidelines and regulations of Soochow University. The methods were carried out in accordance with the approved guidelines. The study was approved by the Medical Ethics Committee of Soochow University (No. Sdfey201005). The parents of all study participants gave both verbal and written informed consent before study enrollment.

**Patients.** This retrospective study was conducted from January 2010 to December 2012 in pediatric patients at the Department of Respiratory Disease of the Affiliated Children’s Hospital, Sozhu University. The diagnosis of bronchiolitis was based on the following criteria: (1) The disease occurred within two years of birth. (2) The onset was acute, accompanied by wheezing and dyspnea, and a previous history of upper respiratory tract infection. (3) The patient presented with restlessness, increased respiration and heart rate, nasal symptoms, and cyanosis. (4) Physical examination revealed widespread double lung wheeze during the onset of wheezing, accompanied by fine rales or crepitus. Patients with congenital heart disease, immune deficiency, bronchus, or pulmonary dysplasia were excluded in this study.

**Sputum specimen collection.** Nasopharyngeal secretions were collected from each study participant within 24 h after admission by a lab technician as previously described. Briefly, an aseptic plastic sputum catheter was inserted into the nostril to a depth of about 7–8 cm until reaching the pharynx. Approximately 2 ml of nasopharyngeal secretions was collected by applying negative pressure. The sample was mixed with 4–8 ml PBS, and centrifuged for 10 minutes at 300–500 rpm. The supernatant was discarded and the pellet was mixed with 4–8 ml PBS and centrifuged for an additional 10 minutes. The pellet was stored at −80 °C until testing began.

**Sputum MP-DNA detection and evaluation.** DNA lysate (Shanghai Shenyu biotechnology company, Shanghai, China) was added to the sputum pellet following washing with PBS. The sample was heated to 95 °C for 10 min, centrifuged for 5 min at 12,000 rpm, and then the supernatant was collected. After extracting the DNA from the sputum specimen, MP DNA was detected by fluorescent real-time PCR (BIO-RAD iCycler, USA). The cyclic temperature settings were 93 °C for 10 min, centrifuged for 7 min; hMPV was assayed by fluorescent real-time PCR (BIO-RAD iCycler). The cyclic temperature settings were 94 °C, 30 s; 56 °C, 30 s; 72 °C, 30 s; amplified by 40 cycles. The primer sequences and MP probe are shown in Table 3.

**Table 3 | Amplification of MP, hMPV and hBoV genes**

| Gene  | Sequence                                                                 | Size (bp) |
|-------|---------------------------------------------------------------------------|-----------|
| MP    | Forward 5'-CCCCAACCACAACTGGCAGCTCA3'                                      | 76        |
|       | Reverse 5'-ACCACGCTAATGACCTGAAT3'                                         |           |
|       | Probe 5'-FAM-TCAACTCATGAAT3'                                               | 213       |
| hMPV  | Forward 5'-AACCGGTGACTAAGTGATGGGCGTAC3'                                   |           |
|       | Reverse 5'-CATTGTTATGACAGCCGCCCCTA3'                                       |           |
|       | Probe 5'-TGACATCAGAACACTAAAACGCCTG3'                                       | 92        |
| hBoV  | Forward 5'-CAGATCTTTCITTCCTTCCTCAATAAC3'                                   |           |
|       | Probe 5'-FAM-AGGACCGCAAAAACACCTCTAGGGG-3'TAMRA                             |           |

MP, Mycoplasma pneumonia; hMPV, human metapneumovirus; hBoV, human bocavirus; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.

**RNA extraction and real-time PCR to detect the human metapneumovirus (hMPV) gene.** RNA was extracted from sputum specimens using Trizol (Invitrogen, USA). cDNA was synthesized by reverse transcription. The cyclic temperature settings were 94 °C, 30 s; 55 °C, 30 s; 68 °C, 30 s; amplified by 45 cycles with the last at 68 °C for 7 min. hMPV was assayed by fluorescent real-time PCR (BIO-RAD iCycler). The cyclic temperature settings were 94 °C, 30 s; 56 °C, 30 s; 72 °C, 30 s; amplified, 40 cycles. The primer sequences for hMPV are shown in Table 3.

**DNA extraction and real-time PCR to detect the human bocavirus (hBoV) gene.** Sputum DNA was extracted as described above, and hBoV-DNA was detected by real-time PCR. The cyclic temperature settings were 94 °C, 30 s; 56 °C, 30 s; 72 °C, 30 s; amplified by 40 cycles. The primer sequences and hBoV probe are shown in Table 3.

**Statistical analysis.** All data were analyzed using PASW 20.0 statistical software (IBM, USA). The comparisons among groups were performed using the chi square test. For data that did not meet the conditions of the chi square test, Fisher’s exact probability test was used. Data with nonnormal distributions, were expressed as medians and quartile ranges (M; P25 P75) and differences were evaluated using the Mann–Whitney U test. P < 0.05 was considered significant.

1. Zenta, S. E. Care of infants and children with bronchiolitis: a systematic review. *J Pediatr Nurs* 26, 519–529 (2011).
2. Hervas, D. et al. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. *Eur J Clin Microbiol Infect Dis* 31, 1975–1981 (2012).
3. Miller, E. K. et al. Viral etiologies of infant bronchiolitis, group and upper respiratory illness during 4 consecutive years. *Pediatr Infect Dis J* 32, 950–955 (2013).
4. Dellipini, A. et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. *Respir Med* 102, 1762–1768 (2008).
5. Hadi, N., Kashef, S., Moazzen, M., Pour, M. S. & Rezaei, N. Survey of Mycoplasma pneumoniae in Iranian children with acute lower respiratory tract infections. *Braz J Infect Dis* 15, 97–101 (2011).
6. Hoffmann, J. et al. Viral and atypical bacterial etiology of acute respiratory infections in children under 5 years old living in a rural tropical area of Madagascar. *PLOS One* 7, e43666 (2012).
7. Libre, J. M., Urban, A., Garcia, E., Carrasco, M. A. & Murcia, C. Bronchiolitis obliteratoris organizing pneumonia associated with acute Mycoplasma pneumoniae infection. *Clin Infect Dis* 25, 1340–1342 (1997).
8. Natori, H. et al. Organizing pneumonia associated with Mycoplasma pneumoniae infection. *Ipn J Radiol* 28, 688–691 (2010).
9. Watanabe, H., Uruma, T., Nakamura, H. & Aoshiba, K. The role of Mycoplasma pneumoniae in infant bronchiolitis. *Allergy Asthma Proc* 35, 204–210 (2014).
10. Cosentini, R. et al. Severe asthma exacerbation: role of acute Chlamydia pneumoniae and Mycoplasma pneumoniae infection. *Respir Med* 9, 48 (2008).
11. Hong, S. J. The Role of Mycoplasma pneumoniae Infection in Asthma. *Allergy Asthma Immunol Res* 4, 59–61 (2012).
12. Sung, R. Y., Chan, R. C., Tam, J. S., Cheng, A. F. & Murray, H. G. Epidemiology and aetiology of acute bronchiolitis in Hong Kong infants. *Epidemiol Infect* 108, 147–154 (1992).
13. Bezerra, P. G. et al. Viral and atypical bacterial detection in acute respiratory infection in children under five years. *PLOS One* 6, e19829 (2011).
14. American Academy of Pediatrics. Subcommittee on Diagnosis and Management of Bronchiolitis. *Pediatrics* 117, 1774–1793 (2006).
15. Liu, W. K. et al. Epidemiology of acute respiratory infections in children in Guangzhou: a three-year study. *PLOS One* 9, e96674 (2014).
16. Pientong, C. et al. Atypical bacterial pathogen infection in children with acute bronchiolitis in northeast Thailand. *J Microbiol Immunol Infect* 44, 95–100 (2011).
17. Skakni, L. et al. Detection of Mycoplasma pneumoniae in clinical samples from pediatric patients by polymerase chain reaction. *J Clin Microbiol* 30, 2638–2643 (1992).
18. Kleemola, S. R., Karjalainen, J. E. & Raty, R. K. Rapid diagnosis of Mycoplasma pneumoniae infection: clinical evaluation of a commercial probe test. *J Infect Dis* **162**, 70–75 (1990).

19. Ji, W. *et al.* Etiology of acute respiratory tract infection in hospitalized children in Suzhou from 2005 to 2011. *Zhonghua Yu Fang Yi Xue Za Zhi* **47**, 497–503 (2013).

20. Chen, Z. *et al.* Epidemiology and associations with climatic conditions of Mycoplasma pneumoniae and Chlamydia pneumoniae infections among Chinese children hospitalized with acute respiratory infections. *Ital J Pediatr* **39**, 34 (2013).

21. Ke, L. Q., Wang, F. M., Li, Y. J. & Luo, Y. C. Epidemiological characteristics of Mycoplasma pneumoniae pneumonia in children. *Zhongguo Dang Dai Er Ke Za Zhi* **15**, 33–36 (2013).

22. Waites, K. B. New concepts of Mycoplasma pneumoniae infections in children. *Pediatr Pulmonol* **36**, 267–278 (2003).

23. Sidal, M. *et al.* Frequency of Chlamydia pneumoniae and Mycoplasma pneumoniae infections in children. *J Trop Pediatr* **53**, 225–231 (2007).

24. Foy, H. M., Kenny, G. E., Cooney, M. K. & Allan, I. D. Long-term epidemiology of infections with Mycoplasma pneumoniae. *J Infect Dis* **139**, 681–687 (1979).

25. Nolevaux, G. *et al.* Epidemiological and clinical study of Mycoplasma pneumoniae respiratory infections in children hospitalized in a pediatric ward between 1999 and 2005 at the Reims University Hospital. *Arch Pediatr* **15**, 1630–1636 (2008).

26. Othman, N., Isaacs, D. & Kesson, A. Mycoplasma pneumoniae infections in Australian children. *J Paediatr Child Health* **41**, 671–676 (2005).

27. Xia, Y., Wu, C. K., Tang, Y. Y. & Cao, J. Differences in the clinical features of Mycoplasma pneumoniae pneumonia among children of different ages. *Zhongguo Dang Dai Er Ke Za Zhi* **15**, 179–182 (2013).

28. Youn, Y. S. *et al.* Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. *BMC Pediatr* **10**, 48 (2010).

29. Hu, Y. M. & Jiang, Z. F. [Bronchiolitis] *Zhu Futang Practical Pediatrics* [Hu, Y. M.(ed.)][1163–1199] (Peoples Health Publishing House, Beijing, 2002).

**Acknowledgments**

This work was supported by Science and Technology Projects of Jiangsu Medical Department (Grant No. H201315).

**Author contributions**

Y.Q.W. and C.L.H. wrote the main manuscript text and W.J. and Y.D.Y. collected and analyzed data. X.J.S. and J.X. detected *Mycoplasma pneumoniae*. All authors reviewed the manuscript.

**Additional information**

Competing financial interests: The authors declare no competing financial interests.

**How to cite this article:** Wang, Y. *et al.* Bronchiolitis Associated With *Mycoplasma Pneumoniae* in Infants in Suzhou China Between 2010 and 2012. *Sci. Rep.* **5**, 7846; DOI:10.1038/srep07846 (2015).

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/